Adaptimmune Therapeutics PLC (ADAP)
0.6366
-0.03
(-4.23%)
USD |
NASDAQ |
Nov 21, 16:00
0.634
0.00 (0.00%)
After-Hours: 20:00
Adaptimmune Therapeutics Price to Free Cash Flow
Price to Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Price to Free Cash Flow Data
| Date | Value |
|---|---|
| March 30, 2022 | -- |
| March 29, 2022 | -- |
| March 28, 2022 | -- |
| March 25, 2022 | -- |
| March 24, 2022 | -- |
| March 23, 2022 | -- |
| March 22, 2022 | -- |
| March 21, 2022 | -- |
| March 18, 2022 | -- |
| March 17, 2022 | -- |
| March 16, 2022 | -- |
| March 15, 2022 | -- |
| March 14, 2022 | -- |
| March 11, 2022 | -- |
| March 10, 2022 | -- |
| March 09, 2022 | -- |
| March 08, 2022 | -- |
| March 07, 2022 | -- |
| March 04, 2022 | -- |
| March 03, 2022 | -- |
| March 02, 2022 | -- |
| March 01, 2022 | -- |
| February 28, 2022 | -- |
| February 25, 2022 | -- |
| February 24, 2022 | -- |
| Date | Value |
|---|---|
| February 23, 2022 | -- |
| February 22, 2022 | -- |
| February 18, 2022 | -- |
| February 17, 2022 | -- |
| February 16, 2022 | -- |
| February 15, 2022 | -- |
| February 14, 2022 | -- |
| February 11, 2022 | -- |
| February 10, 2022 | -- |
| February 09, 2022 | -- |
| February 08, 2022 | -- |
| February 07, 2022 | -- |
| February 04, 2022 | -- |
| February 03, 2022 | -- |
| February 02, 2022 | -- |
| February 01, 2022 | -- |
| January 31, 2022 | -- |
| January 28, 2022 | -- |
| January 27, 2022 | -- |
| January 26, 2022 | -- |
| January 25, 2022 | -- |
| January 24, 2022 | -- |
| January 21, 2022 | -- |
| January 20, 2022 | -- |
| January 19, 2022 | -- |
Price to Cash Flow Definition
Price to free cash flow measures the Price / TTM Free Cash Flow. Like other price ratios (ie. PE Ratio, PS Ratio, P/B Ratio), this metric can be used to compare companies with similar capital structures. Free cash flow gives an idea of how much cash is available for shareholders through stock buybacks and dividend payouts. A lower price to free cash flow is more desirable when assessing different companies.